Market Research Logo

United Kingdom Metered Dose Inhaler Devices Market Outlook to 2023

United Kingdom Metered Dose Inhaler Devices Market Outlook to 2023

Summary

GlobalData’s new report, United Kingdom Metered Dose Inhaler Devices Market Outlook to 2023, provides key market data on the United Kingdom Metered Dose Inhaler Devices market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for Metered Dose Inhaler Devices.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

  • Market size and company share data for Metered Dose Inhaler Devices.
  • Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.
  • 2016 company shares and distribution shares data for each of the market segments.
  • Global corporate-level profiles of key companies operating within the United Kingdom Metered Dose Inhaler Devices market.
  • Key players covered include GlaxoSmithKline Plc, AstraZeneca Plc and Boehringer Ingelheim GmbH.
Reasons to buy
  • Develop business strategies by identifying the key market segments poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Metered Dose Inhaler Devices Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Metered Dose Inhaler Devices Market, United Kingdom
3.1 Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), 2009-2016
3.2 Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), 2016-2023
3.3 Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), 2009-2016
3.4 Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), 2016-2023
3.5 Metered Dose Inhaler Devices Market, United Kingdom, Average Price ($), 2009-2023
3.6 Metered Dose Inhaler Devices Market, United Kingdom, Distribution Share by Revenue ($m), 2015-2016
3.7 Metered Dose Inhaler Devices Market, United Kingdom, Company Share by Revenue ($m), 2016
4 Overview of Key Companies in United Kingdom, Metered Dose Inhaler Devices Market
4.1 GlaxoSmithKline Plc
4.1.1 Company Overview
4.2 AstraZeneca Plc
4.2.1 Company Overview
4.3 Boehringer Ingelheim GmbH
4.3.1 Company Overview
4.4 Pfizer Inc
4.4.1 Company Overview
4.5 Merck & Co Inc
4.5.1 Company Overview
5 Financial Deals Landscape
5.1 Debt Offerings
5.1.1 Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020
6 Recent Developments
6.1 Corporate Communications
6.1.1 May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors
6.1.2 Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer
6.1.3 Mar 22, 2017: BioStable Science & Engineering Announces FDA Clearance of the HAART 300 Aortic Annuloplasty Device
6.1.4 Mar 06, 2017: Vectura Group: Board Change
6.1.5 Dec 14, 2016: Consort Medical: Directorate Change
6.1.6 Nov 25, 2016: Consort Medical: CFO Appointment
6.1.7 Aug 17, 2016: Consort Medical Announces Directorate Change
6.1.8 Jul 08, 2016: Dr John Brown, Non-Executive Director, confirms date to step down
6.2 Financial Announcements
6.2.1 Jun 15, 2017: Consort Medical: Full year results
6.2.2 May 31, 2017: Lamellar Biomedical Recruits First Patients into Clinical Study Assessing LAMELLEYE for Treatment of Dry Eye Disease
6.2.3 May 10, 2017: Mylan Reports First Quarter 2017 Results
6.2.4 Apr 05, 2017: InVivo Therapeutics Announces New Patient Enrollment into the INSPIRE Study at the Carolinas Medical Center
6.2.5 Mar 29, 2017: Peer-Reviewed Clinical Study Shows ID Genomics’ Bacterial Fingerprinting Technology Can Reduce Prescription Errors and Antibiotic Overuse at the Point-of-Care
6.2.6 Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016
6.2.7 Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016
6.2.8 Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance
6.2.9 Dec 06, 2016: Consort Medical Reports Interim Results Results For The Six Months Ended 31 October 2016
6.2.10 Nov 09, 2016: Mylan Reports Third Quarter 2016 Results
6.2.11 Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8%
6.3 Other Significant Developments
6.3.1 Feb 16, 2017: Vectura achieves £9 million royalty cap from GSK Ellipta® products
6.3.2 Jan 11, 2017: Vectura Group: Pre-close update
6.3.3 Sep 07, 2016: New Scale-Up and Commercial Supply Agreement
7 Appendix
7.1 Research Methodology
7.1.1 Coverage
7.1.2 Secondary Research
7.1.3 Primary Research
7.1.4 Company Share Analysis
7.1.5 Distribution Share Analysis
7.1.6 Benchmarking
7.2 GlobalData Consulting
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2009-2016
Table 2: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2016-2023
Table 3: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Historic, 2009-2016
Table 4: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Forecast, 2016-2023
Table 5: Metered Dose Inhaler Devices Market, United Kingdom, Average Price ($), Historic, 2009-2016
Table 6: Metered Dose Inhaler Devices Market, United Kingdom, Average Price ($), Forecast, 2016-2023
Table 7: Metered Dose Inhaler Devices Market, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2015-2016
Table 8: Metered Dose Inhaler Devices Market, United Kingdom, Company Share by Revenue ($m), USD Constant, 2016
Table 9: Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020
1.2 List of Figures
Figure 1: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2009-2016
Figure 2: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2016-2023
Figure 3: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Historic, 2009-2016
Figure 4: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Forecast, 2016-2023
Figure 5: Metered Dose Inhaler Devices Market, United Kingdom, Company Share (%) 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report